NCT07035392

Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

A Single-arm, Prospective, Multicenter Clinical Study of Adebrelimab in Combination With Chemotherapy Neoadjuvant Therapy to Resect Non-small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Zhangzhou Municipal Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is a single arm, prospective, multicenter clinical trial, and eligible patients will receive the following treatment regimen: Adebrelimab combined with chemotherapy.The study includes a screening period (from the signing of informed consent by the subjects to no more than 28 days before the first medication, imaging examinations are allowed to be performed within 28 days before the first medication, and tumor tissue biopsy is allowed to be archived within 6 months before the first medication), a treatment period (including neoadjuvant and surgical treatment), and a follow-up period (including safety follow-up and survival follow-up).

Conditions

• Adebrelimab (SHR-1316)
• NSCLC
• Chemotherapy

Interventions

Type	Name	Description
DRUG	Adebrelimab	Adebrelimab 1200mg，ivgtt，D1，Q3W
DRUG	chemotherapy	Queue A (lung squamous cell carcinoma patients): Albumin paclitaxel 260mg/m2, ivgtt，D1 , Q3W Carboplatin AUC=5, D1，Q3W Queue B (lung adenocarcinoma patients): Pemetrexed 500 mg/m2, ivgtt，D1，Q3W Carboplatin AUC=5, D1，Q3W

Timeline

• Start date: 2025-06-20
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-06-25
• Last updated: 2025-06-25